In August 2021, HJF received patents in the United States, Australia, and Europe for an innovative treatment for allergies or other autoimmune diseases using a homogenate of Caenorhabditis elegans antigens.
This new technology focuses on using a non-pathogenic, non-parasitic worm, specifically using a composition created from a single strain, C. elegans.
The cellular transmembrane protein serine incorporator 5 (SERINC5) has been identified as an HIV-1 restriction factor. The characterization of SERINC5 protein expression and sub-cellular localization has been limited to exogenously expressed SERINC5 as very few monoclonal antibodies (mAbs) of sufficient specificity and sensitivity are currently available.
Identifying Potential Treatments for Leukemias and Other Cancers
Researchers at USU and HJF have identified compounds to inhibit the activity of SETBP1. Researchers have carried out screening and lead identification work to identify molecules that could block the interactions with SETbp1.
Researchers at USU and HJF have developed a novel approach to develop better functioning of inactivated vaccines. The method applies the synthetic antioxidant complex Mn-decapeptide-phosphate (MDP) during the irradiation process to selectively protect cell proteins – but not nucleic acids – from radiation induced oxidative damage.
Researchers at HJF and collaborators have identified several monoclonal antibodies (mAbs) with a wide range of capabilities to precisely neutralize ZIKV or potently cross-neutralize ZIKV and DENV.
HJF's award-winning technology transfer team is the trusted and proven partner of choice for licensing new innovative medical technologies. HJF has longstanding relationships with researchers across the DoD and Federal Government. HJF's patents cover a broad range of focus areas from infectious disease to cancer, from vaccines to medical devices.
Contact our technology transfer team to learn about the current list of technologies available for licensing.
HJF is your go-to organization for tech transfer between HJF's research partners and private industry. Our long-standing relationships with scientists, combined with our outstanding expertise in research and technology, enable us to facilitate all aspects of technology transfer. From introduction, to discovery, collaboration, and licensing, HJF can connect companies to researchers in nearly any area of medicine.
